AZ-话题@MedSci

#AZ#

260篇内容 | 4204人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1714890, encodeId=d4de1e14890bd, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=曙方医药与Minoryx达成神经系统罕见病新药Leriglitazone在中国内地、香港及澳门的**授权协议, objectType=article, longId=201120, objectId=e8f320112070, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8f320112070, replyNumber=0, likeNumber=57, createdTime=2021-05-05, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8f320112070, moduleTitle=曙方医药与Minoryx达成神经系统罕见病新药Leriglitazone在中国内地、香港及澳门的**授权协议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8f320112070)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714891, encodeId=5c881e1489171, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Braz Oral Res：含中草药纳米颗粒漱口水的抗生物膜和抗炎作用, objectType=article, longId=201349, objectId=f588201349b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f588201349b5, replyNumber=0, likeNumber=80, createdTime=2020-12-30, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f588201349b5, moduleTitle=Braz Oral Res：含中草药纳米颗粒漱口水的抗生物膜和抗炎作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f588201349b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714881, encodeId=21121e1488151, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Braz J Otorhinolaryngol：MicroRNA-223-3p通过靶向INPP4A来调节过敏性炎症 , objectType=article, longId=197872, objectId=b41b19e872bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b41b19e872bb, replyNumber=0, likeNumber=63, createdTime=2020-09-08, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b41b19e872bb, moduleTitle=Braz J Otorhinolaryngol：MicroRNA-223-3p通过靶向INPP4A来调节过敏性炎症 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b41b19e872bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714887, encodeId=294a1e14887ae, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=FDA批准Onureg（azacitidine）治疗急性髓细胞性白血病（AML）, objectType=article, longId=200392, objectId=7b192003927b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b192003927b, replyNumber=0, likeNumber=71, createdTime=2020-10-04, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b192003927b, moduleTitle=FDA批准Onureg（azacitidine）治疗急性髓细胞性白血病（AML）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b192003927b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714907, encodeId=060e1e1490768, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=法布瑞氏症如何治疗？Fabrazyme（阿加糖苷酶beta）的长期数据, objectType=article, longId=208447, objectId=c6e320844e56, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6e320844e56, replyNumber=0, likeNumber=52, createdTime=2021-06-09, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6e320844e56, moduleTitle=法布瑞氏症如何治疗？Fabrazyme（阿加糖苷酶beta）的长期数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6e320844e56)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714908, encodeId=c0ca1e1490804, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=阿斯利康COVID-19疫苗AZD1222，“没有证据”显示增加血栓风险, objectType=article, longId=208449, objectId=374820844956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=374820844956, replyNumber=0, likeNumber=60, createdTime=2022-01-07, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=374820844956, moduleTitle=阿斯利康COVID-19疫苗AZD1222，“没有证据”显示增加血栓风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=374820844956)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714898, encodeId=75971e14898bb, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=再生元的Inmazeb成为获得FDA批准的埃博拉病毒治疗药物, objectType=article, longId=202131, objectId=d48b202131f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d48b202131f6, replyNumber=0, likeNumber=42, createdTime=2021-02-12, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d48b202131f6, moduleTitle=再生元的Inmazeb成为获得FDA批准的埃博拉病毒治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d48b202131f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714888, encodeId=81fd1e1488803, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Braz J Otorhinolaryngol：骨锚式助听器的两种手术技术比较：它们的手术和听力学结果有何不同？, objectType=article, longId=200744, objectId=09f9200e447a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09f9200e447a, replyNumber=0, likeNumber=76, createdTime=2020-10-09, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09f9200e447a, moduleTitle=Braz J Otorhinolaryngol：骨锚式助听器的两种手术技术比较：它们的手术和听力学结果有何不同？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09f9200e447a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714895, encodeId=e9e91e14895fa, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=阿斯利康将在COVID-19试验中测试长效抗体AZD7442（两种单克隆抗体的混合物）, objectType=article, longId=201925, objectId=8cbd20192559, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8cbd20192559, replyNumber=0, likeNumber=70, createdTime=2021-06-13, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8cbd20192559, moduleTitle=阿斯利康将在COVID-19试验中测试长效抗体AZD7442（两种单克隆抗体的混合物）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8cbd20192559)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714880, encodeId=9fa11e148805e, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=FDA批准地西他滨/cedazuridine联合治疗骨髓增生异常综合征, objectType=article, longId=197791, objectId=327a19e79151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=327a19e79151, replyNumber=0, likeNumber=97, createdTime=2020-08-30, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=327a19e79151, moduleTitle=FDA批准地西他滨/cedazuridine联合治疗骨髓增生异常综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=327a19e79151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714883, encodeId=81c21e1488374, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=今日要闻：日本同意购买AZ新冠疫苗，药明开展疫苗的CDMO业务, objectType=article, longId=199562, objectId=0fba1995621f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fba1995621f, replyNumber=0, likeNumber=122, createdTime=2021-01-25, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fba1995621f, moduleTitle=今日要闻：日本同意购买AZ新冠疫苗，药明开展疫苗的CDMO业务, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fba1995621f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714882, encodeId=73a61e1488273, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Braz J Otorhinolaryngol：嗅觉丧失与COVID-19关系紧密 , objectType=article, longId=197919, objectId=034519e919e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=034519e919e7, replyNumber=0, likeNumber=84, createdTime=2021-02-05, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=034519e919e7, moduleTitle=Braz J Otorhinolaryngol：嗅觉丧失与COVID-19关系紧密 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=034519e919e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714877, encodeId=63ea1e14877be, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Pirbright研究所证明，两剂ChAdOx1 nCoV-19（AZD1222）疫苗可增强猪的免疫反应, objectType=article, longId=196432, objectId=51c11964320e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51c11964320e, replyNumber=0, likeNumber=88, createdTime=2021-05-07, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51c11964320e, moduleTitle=Pirbright研究所证明，两剂ChAdOx1 nCoV-19（AZD1222）疫苗可增强猪的免疫反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51c11964320e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714902, encodeId=94671e149028c, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=World Allergy Organ J：MP-AzeFlu对过敏性鼻炎和哮喘患者的哮喘治疗实际效果评估, objectType=article, longId=205537, objectId=e16b20553ecb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e16b20553ecb, replyNumber=0, likeNumber=66, createdTime=2021-10-18, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e16b20553ecb, moduleTitle=World Allergy Organ J：MP-AzeFlu对过敏性鼻炎和哮喘患者的哮喘治疗实际效果评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e16b20553ecb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714900, encodeId=d88b1e14900ab, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Braz Oral Res：白千层或可用于口腔抗菌，防治龋齿和牙周炎, objectType=article, longId=203291, objectId=17f2203291ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17f2203291ef, replyNumber=0, likeNumber=72, createdTime=2021-03-23, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17f2203291ef, moduleTitle=Braz Oral Res：白千层或可用于口腔抗菌，防治龋齿和牙周炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17f2203291ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714903, encodeId=d9771e14903bd, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=J Am Soc Nephrol：抗IL-6抗体clazakizumab对抗体介导的排斥反应的有利作用, objectType=article, longId=205782, objectId=e8ea205e8249, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8ea205e8249, replyNumber=0, likeNumber=69, createdTime=2021-04-14, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8ea205e8249, moduleTitle=J Am Soc Nephrol：抗IL-6抗体clazakizumab对抗体介导的排斥反应的有利作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8ea205e8249)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714893, encodeId=c6db1e14893ea, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Braz Oral Res：甲硝唑联合阿莫西林辅助治疗种植体周围炎中的效果, objectType=article, longId=201383, objectId=ea70201383c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea70201383c5, replyNumber=0, likeNumber=83, createdTime=2021-01-23, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea70201383c5, moduleTitle=Braz Oral Res：甲硝唑联合阿莫西林辅助治疗种植体周围炎中的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea70201383c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714863, encodeId=685d1e14863ec, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Blaze Bioscience的光学成像剂BLZ-100用于"点亮"儿童中枢神经系统肿瘤，获FDA授予快速通道指定, objectType=article, longId=191725, objectId=4cf9191e258a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cf9191e258a, replyNumber=0, likeNumber=82, createdTime=2021-03-10, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cf9191e258a, moduleTitle=Blaze Bioscience的光学成像剂BLZ-100用于"点亮"儿童中枢神经系统肿瘤，获FDA授予快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cf9191e258a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714901, encodeId=e82c1e149018d, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=J Asthma Allergy：MP-AzeFlu能够改善过敏性鼻炎患者的生活质量, objectType=article, longId=204604, objectId=25ef204604ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25ef204604ac, replyNumber=0, likeNumber=66, createdTime=2021-01-26, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25ef204604ac, moduleTitle=J Asthma Allergy：MP-AzeFlu能够改善过敏性鼻炎患者的生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25ef204604ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714886, encodeId=8d761e1488637, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Int Arch Allergy Immunol：特异性免疫球蛋白E反应和并发症对MP-AzeFlu效果影响的现实生活研究, objectType=article, longId=200225, objectId=57fd2002256b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57fd2002256b, replyNumber=0, likeNumber=72, createdTime=2021-06-18, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57fd2002256b, moduleTitle=Int Arch Allergy Immunol：特异性免疫球蛋白E反应和并发症对MP-AzeFlu效果影响的现实生活研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57fd2002256b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

AZ

2020-05-29

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

曙方医药与Minoryx达成神经系统罕见病新药Leriglitazone在中国内地、香港及澳门的**授权协议

2021-05-05

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Braz Oral Res：含中草药纳米颗粒漱口水的抗生物膜和抗炎作用

2020-12-30

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Braz J Otorhinolaryngol：MicroRNA-223-3p通过靶向INPP4A来调节过敏性炎症

2020-09-08

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

FDA批准Onureg（azacitidine）治疗急性髓细胞性白血病（AML）

2020-10-04

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

法布瑞氏症如何治疗？Fabrazyme（阿加糖苷酶beta）的长期数据

2021-06-09

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

阿斯利康COVID-19疫苗AZD1222，“没有证据”显示增加血栓风险

2022-01-07

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

再生元的Inmazeb成为获得FDA批准的埃博拉病毒治疗药物

2021-02-12

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Braz J Otorhinolaryngol：骨锚式助听器的两种手术技术比较：它们的手术和听力学结果有何不同？

2020-10-09

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

阿斯利康将在COVID-19试验中测试长效抗体AZD7442（两种单克隆抗体的混合物）

2021-06-13

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

FDA批准地西他滨/cedazuridine联合治疗骨髓增生异常综合征

2020-08-30

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

今日要闻：日本同意购买AZ新冠疫苗，药明开展疫苗的CDMO业务

2021-01-25

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Braz J Otorhinolaryngol：嗅觉丧失与COVID-19关系紧密

2021-02-05

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Pirbright研究所证明，两剂ChAdOx1 nCoV-19（AZD1222）疫苗可增强猪的免疫反应

2021-05-07

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

World Allergy Organ J：MP-AzeFlu对过敏性鼻炎和哮喘患者的哮喘治疗实际效果评估

2021-10-18

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Braz Oral Res：白千层或可用于口腔抗菌，防治龋齿和牙周炎

2021-03-23

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

J Am Soc Nephrol：抗IL-6抗体clazakizumab对抗体介导的排斥反应的有利作用

2021-04-14

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Braz Oral Res：甲硝唑联合阿莫西林辅助治疗种植体周围炎中的效果

2021-01-23

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Blaze Bioscience的光学成像剂BLZ-100用于"点亮"儿童中枢神经系统肿瘤，获FDA授予快速通道指定

2021-03-10

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

J Asthma Allergy：MP-AzeFlu能够改善过敏性鼻炎患者的生活质量

2021-01-26

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Int Arch Allergy Immunol：特异性免疫球蛋白E反应和并发症对MP-AzeFlu效果影响的现实生活研究

2021-06-18

科室
- - 订阅+
  - 更多科室
工具
服务